Successful treatment of c-kit-positive metastatic Adenoid Cystic Carcinoma (ACC) with a combination of curcumin plus imatinib: A case report  by Demiray, M. et al.
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a  b  s  t  r  a  c  t
Adenoid  cystic  carcinoma  (ACC)  is an  aggressive  malignant  neoplasm  of the  secretory  glands.  Conven-
tional  chemotherapy  has  poor  effectiveness  against  metastatic  ACC.  Thus,  a  novel  effective  therapy  is
needed  against  metastatic  ACC.
A majority  of ACCs  (up  to  94%)  express  c-kit.  Imatinib  is monoclonal  antibody  with  speciﬁc  activ-
ity  against  c-kit  but  has  not  been  found  to be effective  in  treating  patients  with  ACC in which  c-kit  is
overexpressed  and  activated.  The  NF-B  and  mTOR  pathways  have  been  shown  that  ubiquitously  and
concurrently  activated,  indicating  that  the  inhibition  of these  pathways  may  represent  a novel  treat-
ment  approach  for patients  with  ACC.  Curcumin  has  been  shown  to inhibit  NF-B and  NF-B-related
pathways.  43-year-old  patient  was diagnosed  ACC  from  submandibular  salivary  gland.  After  complete
resection  of  tumor  adjuvant  radiotherapy  was  initiated.  Seven  years  later  multiple  lung metastases  were
detected  and  ACC was  conﬁrmed  by re-biopsy.  First-line  chemotherapy  failed.  NF-B  and  c-kit  were over-
expressed  in  the metastatic  specimens.  Therefore,  we  treated  the patient  with  metastatic  chemoresistant
ACC  with  imatinib  400  mg/day  and  intravenous  curcumin  225  mg/m2 twice  a week  plus  oral  bioavailable
curcumin  Arantal® 2 ×  84  mg/day.  At 24 months,  we  observed  near  complete  anatomic  and  complete
metabolic  response.  To  our  knowledge,  this  is  the  ﬁrst  report  of  a patient  with  a c-kit-positive  ACC  that
is successfully  treated  with  the  combination  of  imatinib  and curcumin  in an  integrative  approach.
© 2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Adenoid cystic carcinoma (ACC), also known as cylindroma, is a
are but highly aggressive adenocarcinoma arising within secre-
ory glands. It mainly occurs in the salivary glands and breast
issue.1–3 ACC accounts for approximately 22% of all salivary
land malignancies and represents approximately 1% of all head
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and neck malignancies.4 ACCs typically grow at a slower pace
than other carcinomas. However, ACC is regarded as a high-grade
neoplasm, with radical resection predominantly followed by post-
operative radiotherapy consequently as the current treatment of
choice.5–7 Nonetheless, regional and distant recurrences are rel-
atively common following the local treatment of primary ACC
tumors. Hematogenous metastasis is common, particularly to lung,
bone, and liver.5,8
There is currently no consensus regarding the most appro-
priate treatment of metastatic ACC, with ACC typically resistant
to systemic chemotherapy. Laurie et al. evaluated the effective-
ness of chemotherapy for ACC and reported a mean survival
of 11 months in a patient with metastatic ACC and that the
major objective responses were rare, with stable disease being
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Fig. 1. Staining of the biopsy specimen of a metastatic mass with Papanicolaou (Pap)
stain. (PAP staining; ×100).
Fig. 2. Tubules and cribriform nests of basaloid cells lining cystic spaces ﬁlled with
homogenous material [hematoxylin and eosin (H&E); × 200].M. Demiray et al. / Complementary 
ore common.9 Molecular targeted therapies have therefore been
valuated because of the poor response of ACC to conventional
hemotherapy. Up to 94% of patients with ACCs reportedly express
-kit (also known as CD117) proto-oncogene,10 which may repre-
ent a future therapeutic target. Imatinib is an inhibitor of several
rotein-thyrosine kinases, including those associated with break-
oint cluster region-abelson (Bcr-Abl), platelet-derived growth
actor receptors (PDGF-R), and c-kit.11 Imatinib has demonstrated
ntitumor activity for the inhibition of tyrosine-kinase proteins.
he tumor control rate of imatinib is reportedly over 80% in patients
ith Gastrointestinal Stromal Tumors (GIST). Six studies have
reviously assessed the impact of imatinib in the treatment of
CC, with only two objective responses reported in 71 evaluable
atients.9 It is suggested that c-kit may  play a key role by accelerat-
ng mobilization of tumor cells.12 However, since the data regarding
he effect of c-Kit inhibition on ACC are conﬂicting, reducing c-Kit
ctivity may  not be sufﬁcient to inhibit ACC’s progression.12
Curcumin, a polyphenol, is the major biologically active com-
onent of turmeric that is derived from the dried rhizome of the
urcuma longa plant.13 Recent evidence has indicated curcumin
uppresses all three stages of carcinogenesis: initiation, promotion,
nd progression.14 Curcumin is a highly pleiotropic molecule that
odulates numerous targets including the activation of transcrip-
ion factors, receptors, kinases, cytokines, enzymes, and growth
actors.15 Due to the pleiotropic nature of curcumin, curcumin has
een shown to potentiate the effectiveness of imatinib and have
tility in overcoming imatinib resistance.16,17 Sun et al. demon-
trated curcumin as a potent inhibitor of ACC progression in vitro
nd in vivo.18
Herein, we report a patient with a c-kit-positive ACC treated
ith curcumin plus imatinib.
. Case presentation
In September 2013, a 50-year-old male patient with a seven
ear-history of ACC was admitted to our Oncology Clinic because
f multiple lung metastases and failure of ﬁrst-line chemotherapy.
Seven years ago, in October 2006, the patient presented to the
ar, Nose, and Throat (ENT) Clinic with a complaint of painless,
low-growing mass under the jaw for about two and a half years. He
as medically ﬁt. Clinical examination revealed a freely mobile ﬁrm
ubmandibular mass, measuring approximately 3 × 3 cm.  The rest
f the head and neck examination was within normal limits, with
o evidence of lymphadenopathy. Patient was life time non-smoker
nd he did not have any comorbid disease. Ultrasonographic evalu-
tion detected a submandibular mass originating from the salivary
land and measuring 3.5 × 3 cm in size. Because of the suspicious
onographic appearance, ﬁne needle aspiration biopsy was  per-
ormed stat. The result conﬁrmed the diagnose of Adenoid Cystic
arcinoma (ACC), and after surgery it was staged as T2 (3.5 cm)  N0
0 stage III. Perineurial, but not lymphatic invasion was  observed.
adiotherapy at a total dose of 60 Gy was initiated following resec-
ion with a 1-mm safe margin.
Seven years later, the patient was re-admitted with fatigue and
hortness of breath. Multiple metastatic masses with a maximum
iameter of 75 mm  were detected by computed tomography (CT)
maging. Re-biopsy of a metastatic mass was performed and con-
rmed metastatic ACC to lung (Figs. 1 and 2). A standard 3-week
egimen of cisplatin (80 mg/m2 day 1) plus etoposide (100 mg/m2
ays 1–3) was initiated in the hospital. However, the patient’s
ondition worsened after two cycles of chemotherapy, with CT
can imaging demonstrated progression of the metastatic lesions.
atient’s Eastern Cooperative Oncology Group (ECOG) performance
tatus has changed from ECOG 0 to 1 during last 3 months before
is admission to our clinic.Fig. 3. Adenoid cystic carcinoma demonstrating c-kit expression (c-kit × 400).
In our clinic, ﬁrstly tumor tissue c-kit and Nuclear Factor kappa
B (NF-B) expression were evaluated from re-biopsy material. c-
kit immunohistochemistry demonstrated strongly positive, with
60% of tumoral cells found to express c-kit (Fig. 3). NF-B p65 over
expression was  shown with immunohistochemical method. Patho-
logical evaluation showed +3 positive staining (Fig. 4a, b). F-18
ﬂuorodeoxyglucose (FDG) Positron Emission Tomography – Com-
puted Tomography (PET/CT) was  used in restaging and conﬁrming
metabolically active multiple lung metastases (lung masses SUVmax
4.81 g/ml and mediastinal lymph nodes SUVmax 4.52 g/ml; Fig. 5a,
b).
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Fig. 4. (a and b). Immunohistochemistry adenoid cystic carcinoma tissue labelling
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iaminobenzidine (DAB). [(a) ×100, (b)×400].
After the ﬁrst evaluation, we planned a combination treatment
ith imatinib and off-label use of curcumin integratively. Informed
onsent was provided by the patient, and treatment with ima-
inib 400 mg/day and curcumin administration was  initiated both
rally and intravenously. We  used water soluble and intravenous
dministrable curcumin (Burg-Apotheke, Germany, Patent appli-
ation number: DE 102012219219 A1). One of the authors of the
urrent case report (i.e. HS) has extensive experience of intra-
enous curcumin treatment. According to his experience, dosages
elow 450 mg/m2 is well tolerated by human and only minor and
eversible hematological changes such as echinocyte formation and
Fig. 5. Axial (a) and coronal-fused PET/CT (b) images. Bilaties in Medicine 27 (2016) 108–113
some signs of hemolysis are observed dose dependently, above
the dosages of 300 mg/m2 (unpublished data). Our preclinical data
shows that 225 and 300 mg/m2  dose has similar effect (unpub-
lished data). In total, 225 mg/m2 curcumin in 1000ml normal saline
was administered intravenously over 2–3 h, using a non-di-(2-
ethylhexyl)phthalate (non-DEHP) in-line ﬁlter twice a week. At
30 min  prior to the administration of curcumin, diphenhydramine
50 mg  and ranitidine 50 mg  in 50-ml normal saline was adminis-
tered intravenously over a period of 20 min.
Oral curcumin Arantal® 2 × 2 capsules were also administered.
Arantal® which contains 42 mg  curcumin, is a highly bioavailable
turmeric extract with a solubility in water 4000 times greater than
free curcumin. Two  capsules of Arantal® (84 mg)  are 15 times
more bioavailable than free curcumin in terms of ﬁnal plasma
concentration.19
Tumor responses to treatment were evaluated after 2 months
of treatment by CT and PET. According to RECIST (Response Evalua-
tion Criteria In Solid Tumours) criteria, stable disease was observed.
Metabolic response was deﬁned according to the PET response cri-
teria of the European Organization for Research and Treatment of
Cancer,20 with a partial metabolic response achieved (lung masses
SUVmax 2.30 g/ml and mediastinal lymph nodes metabolic inac-
tive). Accordingly, the patient’s condition was  seen to improve. The
same regimen was  continued for 6 months, with a PET/CT scan
at this time indicating anatomically signiﬁcant reduction of the
tumor masses. The lung lesions were seen to have decreased by
80% in volume, with metabolically signiﬁcant regression observed
(SUVmax 1.03 g/ml) and no uptake in mediastinal lymph nodes
(complete metabolic response; Fig. 6a, b). Oral bio-optimized cur-
cumin Arantal® 2 × 84 mg/day and imatinib 400 mg/day have been
administered since cessation of the 6 months i.v. curcumin treat-
ment. At the most recent evaluation performed in August 2015,
PET/CT imaging demonstrated near complete anatomic and com-
plete metabolic response (Fig. 7a, b). The last check up done in April
2016 showed that physical examination and laboratory evaluation
were normal.
No side effects were observed during the treatment period.
Hematologic and liver function parameters were evaluated weekly
during the ﬁrst 2 months, every 2 weeks during the next 2 months,
and then every 4 months. Intravenous curcumin was  well toler-
ated with no toxicity or adverse reactions observed. Bio-optimized
curcumin (Arantal ) was well tolerated with no toxicity observed.
eral lung metastasis demonstrated high-FDG uptake.
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Fig. 6. PET/CT imaging of the Thorax at 6 months.
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tig. 7. PET/CT imaging of the lung at 24 months. (a, b) PET/CT imaging at 24 mon
complete metabolic response).
. Discussion
Overexpression of c-kit has been reported in the majority of
atients with ACC.10 Imatinib is a speciﬁc inhibitor of Bcr-abl,
DGFR, and c-kit and has demonstrated signiﬁcant effectiveness
n the treatment of mutation-positive diseases such as chronic
yelocytic leukemia (CML) and GIST.21,22 Six studies involving 71
atients have previously assessed imatinib activity in ACC with
bjective responses observed in only two patients.9 However, sta-
le disease was observed in 34 (47%) patients.
Several possibilities may  explain the lack of activity of imatinib
n patients with metastatic ACC with wild-type c-kit expression.
einrich et al. reported response rates to imatinib were depen-
ent on the exact type of mutation present in 127 patients with
IST.23 In patients harboring exon 11 c-kit mutation, the partial
esponse rate was 83.5%, whereas patients with exon 9 c-kit muta-
ion had a partial response rate of 47.8%. In contrast, no objecting
esponses were observed in patients without detectable c-kit or
DGFR mutations.23 However, Vila et al. reported c-kit mutations
re most frequently observed on exons 11 and 9.24 Spontaneous
enomic alterations during disease progression may  also explain
he failure of imatinib. This effect has been well documented inmonstrating signiﬁcant FDG uptake in residual ﬁbronodular densities in the lung
patients with of CML. In the progression phase (accelerated and
blastic phase) of CML, additional genomic alterations develop, sen-
sitivity toward imatinib decreases and, ultimately, the disease
becomes entirely resistant. An analogous pattern may  also be
involved in the progression of metastatic ACC.
Sun et al. demonstrated the Phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3 K)/Akt/Inhibitor of nuclear factor
kappa-B kinase subunit alpha (IKK-)/NF-B pathway is ubiqui-
tously activated in ACC and plays an essential role in the evasion
of apoptosis.25 These experiments indicated agents associated
with downregulation of the PI3 K/Akt/IKK-alpha/NF-B  signaling
pathway may  represent promising therapies for ACC. Meanwhile,
Guo et al. reported curcumin and imatinib exert synergetic
antileukemia effects through the inhibition of imatinib-mediated
overactivation of Akt/mammalian target of rapamycin (mTOR)
signaling and downregulation of Bcr-Abl gene expression.26
Curcumin inhibits cellular proliferation and downregulates con-
stitutive activation of growth-signaling pathways in both newly
diagnosed patients and imatinib-resistant patients.26 Sun et al.
assessed the activation status of both mTOR and NF-B pathways
in relation to PI3K/Akt/IKK signaling both in vivo and in vitro.18 This
study demonstrated that NF-B and mTOR pathways were ubiqui-
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ously and concurrently activated in patients with ACC. However,
urcumin has been shown to signiﬁcantly inhibit in vitro growth,
igration, invasion, and angiogenesis in ACC cells and prevent the
n vivo growth and angiogenesis of ACC tumors in mice through dual
nhibition of both NF-B and mTOR pathways via the PI3K/Akt/IKK
ignaling axis.17 They also reported that concurrent activation of
he mTOR and NF-B pathways was correlated with malignant pro-
ression in ACC. Further, Zhang et al. reported NF-B is involved in
he malignant progression of ACC.27
Curcumin has been shown to inhibit NF-B and NF-B-related
roteins and pathways.28,29 Although almost all ACCs are c-kit
utation positive, the effectiveness of imatinib in such cases is
imited. Six different trials evaluated the effectiveness of imatinib
n metastatic ACC and demonstrated an overall partial response
ate of 2.8%. We  believe ours is the ﬁrst case of ACC successfully
reated with curcumin plus imatinib, indicating the NF-B pathway
s involved in the development and progression of ACC. However,
he effectiveness of curcumin treatment alone for ACC treatment
as not evaluated. We believe combination therapy (imatinib plus
urcumin) represents the most appropriate therapy for ACC in
atients where c-kit and NF-B positivity are detected.
To date, no studies have reported any toxicity associated with
he use of curcumin in either animals or humans.30; however, there
s a low potential for CYP450-mediated drug interactions at phys-
ologic serum concentrations of curcumin. Our clinical experience
ith more than 3000 curcumin infusions in cancer patients sug-
ests that curcumin is safe as no serious negative drug interactions
ave been observed. Preliminary data also indicate curcumin does
ot interact with other chemotherapy agents metabolized and/or
liminated via the primary drug metabolizing CYP450 pathways.31
.1. Strengths and limitations
Therefore, the strength of this study lies in that preclinical in
ivo and in vitro data support the hypothesis of the study that cur-
umin is a safe supplement and has potential clinical utility in the
reatment of metastatic ACC therapy. On the other hand, this study
as several limitations. The ﬁndings are based on a single patient
ithout any comparison group; therefore, statistical signiﬁcance
annot be evaluated in that report. In addition to this, although
ollow-up care is especially important in the ﬁrst ﬁve years after
he treatment, the data presented in this study has been limited
y the observations of 30 month duration of the treatment. Dosage
rrangement of curcumin is based on the unpublished documents
nd previous experience of the authors. Recurrent case reporting or
ase series may  help to strengthen the evidence of this case report.
. Conclusions
Up to date, the effectiveness of curcumin and imatinib, either
lone or in combination, has not been validated in terms of
mproving progression-free survival with complete metabolic and
adiologic responses in patients with ACC. However, curcumin
pparently potentiates and overcomes resistance to chemothera-
eutics and small molecule cancer drugs.
We suggest that besides c-kit, activation of NF-B and mTOR
athways should be evaluated in all ACC patients, and if NF-B and
elated pathways activation is identiﬁed, adding curcumin supple-
entation to treatment plan should be considered.
Integrative medicine brings conventional and complementary
pproaches together in a coordinated way. We  believe that this is
he ﬁrst report of ACC treatment with intravenous and oral bio-
ptimized curcumin with imatinib. Well designed clinical trials
re requested to determine the criteria of patients who  are most
uitable for curcumin combination.ies in Medicine 27 (2016) 108–113
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